CTOs on the Move

Intellipharmaceutics

www.intellipharmaceutics.com

 
We believe that our Hypermatrix technology is a novel and robust controlled-release drug delivery platform. This unique technology allows us to provide life-cycle management or new chemical entity delivery system solutions for virtually any small molecule. The flexibility of this technology allows us to quickly develop complex drug delivery solutions.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Resau Medisca Network

Resau Medisca Network Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.

Watson Laboratories

Watson Laboratories is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oterra

Oterra is the worlds largest natural food color manufacturer, providing naturally sourced colors for the food, beverage, dietary supplements, and pet food industry.

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.